Trial Profile
A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-NegativeMetastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 28 Mar 2016 Number of treatment arms changed from 1 to 2, , according to ClinicalTrials.gov record.
- 28 Mar 2016 Number of treatment arms changed from 1 to 2, , according to ClinicalTrials.gov record.
- 28 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.